
OBIO Stock Forecast & Price Target
OBIO Analyst Ratings
Bulls say
Orchestra BioMed Holdings Inc. demonstrates a favorable financial outlook, highlighted by a total revenue of $987,000 for the third quarter of 2024, surpassing projections of $750,000. The company has also amended the BACKBEAT study protocol, which is anticipated to broaden the eligible patient pool for hypertensive treatments and enhance enrollment speed in the forthcoming months. Furthermore, the net loss of $15.4 million or ($0.41) per share was less than the estimated loss of $16.5 million, indicating improved operational efficiency and financial management.
Bears say
Orchestra BioMed Holdings Inc faces significant risks that could negatively impact its stock performance, including the potential failure of its key product candidates, BackBeat CNT and Virtue SAB, during clinical trials and their inability to secure necessary regulatory approvals. Additionally, there is a concern regarding the commercial viability of these products, as competition and the overall market size may hinder successful market penetration. The risk of potential dilution also presents a financial challenge, further complicating the company's growth prospects and investor confidence.
This aggregate rating is based on analysts' research of Orchestra BioMed Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
OBIO Analyst Forecast & Price Prediction
Start investing in OBIO
Order type
Buy in
Order amount
Est. shares
0 shares